Manufacturing method of an herbal medicinal tablet formulation for treating obesity which can be prescribed based on sasang constitutional medicine

Abstract

An embodiment of the present invention provides a manufacturing method of an herbal medicinal tablet formulation for treating obesity which is prescribed based on Sasang constitutional medicine, comprises manufacturing a concentrated ephedra powder agent so that an ephedrine content is 3.0-4.0%; determining a weight of the concentrated ephedra powder agent according to each constitution of Sasang constitutional medicine, and manufacturing a side effect-preventing powder agent for each constitution to prevent and suppress side effects according to constitution of Sasang constitutional medicine with respect to the weight of the concentrated ephedra powder agent; mixing the concentrated ephedra powder agent and the side effect-preventing powder agent with a variance of a weight ratio therebetween in consideration of weight, obesity, constitution of Sasang constitutional medicine, and side effects; and tableting the mixture of the prepared ephedra powder agent and side effect-preventing powder agent.

Claims

1. A manufacturing method of an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine, comprising: manufacturing a concentrated ephedra powder agent so that an ephedrine content is 3.0-4.0% from an initial ephedra of which initial ephedrine content ranges 0.5-2.5% depending on a producing district and collecting period; manufacturing a side effect-preventing powder agent for each Sasang constitution to prevent and suppress side effects of the ephedrine that are anticipated or known for each Sasang constitution; mixing the concentrated ephedra powder agent and the side effect-preventing powder agent with a variance of a weight ratio therebetween in consideration of weight, obesity, constitution of Sasang constitutional medicine, and side effects; tableting the mixture of the concentrated ephedra powder agent and side effect-preventing powder agent; coating the tablets; after the coating, sorting out defective ones from the coated tablets; and packaging the coated tablets with a label including information prepared according to weight, obesity, constitution of Sasang constitutional medicine, and side effects, wherein the side effect-preventing powder agent for Taeeumin comprises alisma, platycodon, puerariae, acorus gramineus, castanea mollissima, coicis semen, semen raphani, semen armeniacae amarum, cinnamon-vine and semen nelumbinis, the side effect-preventing powder agent for Soyangin comprises talcum, plaster, peppermint, gardeniae fructus, schizonepeta, rhubarb, natrii sulfas, rehmanniae radix cervi and moutan, and the side effect-preventing powder agent for Soeumin comprises ginseng radix, astragali radix, atractylodis macrocephalae rhioma, cinnamon, ginger, poria cocos, zizyphi fructus, hawthorn, Citrus unshiu Markovich and magnoliae cortex, wherein in the mixing the concentrated ephedra powder agent and the side effect-preventing power agent, when the ephedrine content is constant at 3-4%, a weight of the concentrated ephedra powder agent is about 360 g for Taeeumin, about 297 g for Soeumin, and about 360 g for Soyangin, and a weight ratio of the side effect-preventing powder agent for each constitution with respect to a weight of the concentrated ephedra powder agent is about 1:8-10 for Taeeumin, about 1:9-11 for Soeumin, and about 1:8-10 for Soyangin.

2. The manufacturing method of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine of claim 1, wherein the manufacturing of the concentrated ephedra powder agent includes primarily quantifying the ephedrine content in a decoction to be 7 to 8 Brix through Brix measurement every 2 hours in a hydraulic decocting process; and secondarily quantifying the ephedrine content in the decoction to be 30 to 35 Brix through Brix measurement every 2 hours in a vacuum concentration process performed at a temperature from 50° C. to 55° C.

3. The manufacturing method of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine of claim 2, further comprising filtering the decoction through a sieve with a 45 mesh scale to separate out solids larder than the 45 mesh scale after the secondarily quantifying.

4. The manufacturing method of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine of claim 2, wherein the manufacturing of the concentrated ephedra powder agent further includes lyophilizing the decoction to produce the concentrated ephedra powder agent of 30 to 35 Brix that is secondarily quantified, and in the lyophilizing, a freezing condition is 8 hours at a temperature of −30 to −40° C., and a drying condition is at least 60 hours at a temperature of 30 to 40° C.

5. The manufacturing method of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine of claim 4, further comprising measuring and labeling an ephedrine content of the concentrated ephedra powder agent, and airtightly packing the concentrated ephedra powder agent and the side effect-preventing powder agent after the lyophilizing the decoction to produce the concentrated ephedra powder agent and before the mixing the concentrated ephedra powder agent and the side effect-preventing powder agent.

Description

DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 illustrates a photograph of an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to an embodiment of the present invention.

(2) FIG. 2 illustrates a graph analyzing a weight loss ratio after 3 months of taking an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to an embodiment of the present invention.

(3) FIG. 3 illustrates a graph analyzing a change in body fat mass after 3 months of taking an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to an embodiment of the present invention.

(4) FIG. 4 illustrates a graph analyzing a lipase inhibitory ability test of an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to an embodiment of the present invention.

(5) FIG. 5 illustrates a flowchart of a manufacturing method of an ephedra powder agent for an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to an embodiment of the present invention, and a side-effect-preventing powder agent, by constitution.

(6) FIG. 6 illustrates a flowchart of a manufacturing method of an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to an embodiment of the present invention.

(7) FIG. 7 to FIG. 9 respectively illustrate graphs for measuring an ephedrine content every 2 hours for 10 lots in a decocting process for 4 different ephedra with different producing districts and collecting periods so as to manufacture an ephedra powder agent for an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to an embodiment of the present invention.

(8) FIG. 10 and FIG. 11 respectively illustrate graph for explaining a pattern relationship between a Brix content and an ephedrine content in manufacturing an ephedra powder agent for an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to an embodiment of the present invention, by using the results shown in FIG. 7 to FIG. 9.

MODE FOR INVENTION

(9) Hereinafter, the present invention will be described more fully with reference to the accompanying drawings, in which exemplary embodiments of the invention are shown. As those skilled in the art would realize, the described embodiments may be modified in various different ways, all without departing from the spirit or scope of the present invention. Accordingly, the drawings and description are to be regarded as illustrative in nature and not restrictive. Like reference numerals designate like elements throughout the specification.

(10) In the present specification, unless explicitly described to the contrary, the word “comprise” and variations such as “comprises” or “comprising” will be understood to imply the inclusion of stated elements but not the exclusion of any other elements.

(11) First, as shown in FIG. 1, an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to an embodiment of the present invention has the same hardness as a typical tablet formulation; is quickly disintegrated without burdening the stomach when taken with water; has a size of 5.00±30 mm, which is about half the size of a typical tablet formulation, while it has a rectangular shape so that the neck does not feel pain when taking it due to characteristics of an herbal medicine with a large or rough surface; and has a disintegration time within 30 minutes and hardness of about 12.0 kp.

(12) The following Experimental Example 1 was performed on 100 patients who visited the oriental medical clinic of the present applicant in order to configure the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to the embodiment of the present invention described above.

Experimental Example 1

(13) In order to configure the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to the embodiment of the present invention described above, commercially available round, rectangular, triangular, and square tablet formulation shapes; tablet formulations of a typical size, ½ size, and less than ½ size; disintegration times of 20 minutes, 30 minutes, 40 minutes, and a hour; a degree of smearing on the hand; and preference of hardness were determined as very good, good, normal, and bad, and are shown in Table 1.

(14) Table 1 shows the results of investigation for the size, the disintegration degree, the degree of smearing on the hand, and the preference of hardness of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to the embodiment of the present invention

(15) TABLE-US-00001 TABLE 1 Very good Good Normal Bad Shape Rectangle 7 Rectangle 17 Rectangle 34 42 people prefer different shapes Size ½ general ½ general ½ general 30 people prefer size 20 size 31 size 19 about general size or about half or less the general size Disintegration Within 30 Within 30 Within 30 Prefer within 20 minutes 18 minutes 23 minutes 29 minutes Degree of Degree of not Degree of not Degree of not smearing on being smeared being smeared being smeared hand and on hands and on hands and on hands and hardness not easily not easily not easily broken 17 broken 24 broken 27

(16) As shown in Table 1, it was found that 58 out of 100 ordinary people had a preference of ‘Normal’ or more for the rectangular shape; that as for the size, 70 people had a preference of ‘Normal’ or more for about ½ or less than the typical size; that as for the load hardness and the degree of disintegration, 68 people preferred the same hardness as that of the typical tablet formulation and the degree of disintegration that was not smeared on hand and was easily broken; and that 70 people preferred it to disintegrate in water within 30 minutes.

(17) As a result, the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to the embodiment of the present invention was a rectangular tablet formulation and could be prescribed to be stored in a plastic containers for one month; it could be taken with water after meals; it was an herbal medicine, but there was no concern about deterioration when exposed to air, and it was not bulky; and it could solve the problems that may occur when taking common herbal medicines by rapid disintegration, without problems such as smearing when picking up by hand or the peculiar smell or difficult swallowing of typical herbal medicines.

(18) On the other hand, the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to the embodiment of the present invention increased the ephedrine content, which was the target substance (active ingredient) that provided the effect of reducing obesity, to 3.0-4.0% compared to 0.5 to 2.5% that was the content of natural ephedra; it included the ephedra powder agent that achieves medicinal effect stability by maintaining the constant ephedrine content, the side-effect-preventing powder agent for each constitution prescribed by taking into consideration the characteristics of Sasang constitutional medicine constitution, that is, Soeumin, Taeeumin, Soyangin, and Taeyangin in order to alleviate the side effect of the ephedra powder agent, and the disintegrant to provide the hardness and disintegration time corresponding to that of the typical tablet formulation; and the weight ratio of the ephedra powder agent and the side-effect-preventing powder agent for each constitution (hereinafter also referred to as “Gambisan”) was 8-10:1 to 9-11:1.

(19) According to a paper published in September of 2017 in the Journal of Korean Medicine [A Study on the Effectiveness and Stability of Ephedra and Ephedrine in the Treatment of Obesity-Focused on RCT Research], the ephedra and ephedrine-administered groups showed weight and body fat loss when compared to the control group when taken for 20 weeks or more. According to a paper published in 2000 in the International Journal of Obesity, “Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind placebo-controlled pilot study in adolescents.”, compared to the control group, it was found that the combination of ephedrine and caffeine showed a significant weight loss effect; and according to a paper published in 2013 in the international journal “Obesity”, “The Effect of Leptin, Caffeine/Ephedrine and their Combination Upon Visceral Fat Mass and Weight Loss.”, during the 25-week study period, the combination formulation containing ephedrine showed a significant weight loss effect compared to the leptin alone formulation, and in most cases, there was the inconvenience of maintaining the prescription for about 6 months.

(20) The herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to the embodiment of the present invention may be approved by the U.S. FDA up to pseudoephedrine at 240 mg/day, and ephedrine at 150 mg/day for OTC medicine; in the treatment of obese patients, when 5% of the initial weight is lost within 3 months, the effectiveness of the medicine is recognized, and when 10% thereof is lost, successful weight loss is recognized; and particularly, since 5-10% of weight loss may improve obesity-related diseases and reduce complications, the clinical practice guidelines from the Korean Society for Obesity make it possible to achieve an effective obesity reduction effect within 3 months within the range of 150 mg/day, the US FDA-allowed ephedrine content, considering that the goal of weight loss in obese patients is to target 5-10% of their initial weight loss over the course of 3-6 months.

(21) In addition, with respect to the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to the embodiment of the present invention, the lipase activity experiment of Experimental Example 4 below was performed, and it was confirmed that the lipase activity was inhibited as the ephedrine content increased; and through Experimental Example 2, while effective ephedrine content within the range of 150 mg/day, which is the US FDA-allowed ephedrine content, achieved effective weight loss within 3 months for each constitution classified as Soeumin, Soyangin, Taeeumin, and Taeyangin, it was possible to determine the weight ratio of the appropriate ephedra powder and side-effect-preventing powder agent for each constitution with few side effects.

(22) First, the prescription of side-effect-preventing powder agent for each constitution to eliminate each constitutional side effect of ephedra according to Sasang constitutional medicine is as follows.

(23) As shown in Table 2 below, the prescription for the side-effect-preventing powder agent for each constitution was based on the ephedra weight of 1, and had the pharmacological effect supplemented by considering the side effects that occur during diet by constitution, wherein the prescription included medicinal content confirmed through long-term clinical experience, the Sasang Constitutional Journal, the Korean Oriental Internal Medicine Journal, the Botanical List, the Korean Oriental Medicine Journal, and theses.

(24) Table 2 shows the constitutional side effect of Sasang constitutional medicine, the prescription of the side-effect-preventing powder agent for each constitution for preventing this side effect, and the pharmacological effect of each medicinal content.

(25) TABLE-US-00002 TABLE 2 Constitutional side-effect-preventing Pharmacological effect of each Constitutional side effect powder agent herb Taeeumin Taeeumin prescription for side-effect- Gastrointestinal endocrine cell Occurrence of atopic preventing powder agent for each function regulation dermatitis, allergic constitution: alisma 1, platycodon 1, Anti-lipid effect, antioxidant dermatitis, rhinitis, puerariae 1, acorus gramineus1, effect, anti-inflammatory effect bronchial asthma, castanea mollissima 2, coicis semen on allergic reaction urticaria, etc. due to 2, semen raphani 1, semen Anti-obesity effect weak skin, lungs, and armeniacae amarum 1, cinnamon- respiratory system vine 2, semen nelumbinis 2 Soyangin Soyangin prescription for side-effect- Weight loss, improved lipid Clinically, constipation, preventing powder agent for each metabolism, increased heat acne, urinary constitution: talcum 2, plaster 1, metabolism, improved inflammation, etc. peppermint 1, gardeniae fructus 1, constipation, and suppressed fat occurrence schizonepeta 1, rhubarb 1, natrii accumulation effect sulfas 1, rehmanniae radix cervi 2, moutan 1 Soeumin Soeumin prescription for side-effect- Immune activity efficacy, Most frequently preventing powder agent for each Cell protective effect against complained of low blood constitution: ginseng radix 1, oxidative stress, hypoglycemic sugar symptoms such astragali radix 2, atractylodis effect, anti-inflammatory effect, as dizziness and fatigue macrocephalae rhioma 1, cinnamon treatment for atopic dermatitis, during diet 1, ginger 1, poria cocos 1, zizyphi analgesic, sedative effect, fructus1, hawthorn 1, citrus unshiu parasympathetic effect in the markovich 1, magnoliae cortex 1 intestine, etc.

(26) Experimental Example 2 was performed for patients who visited the Korean clinic of the applicant during the 2017 year and prepared an analysis report, wherein the maximum amount of ephedrine content within the range of the US FDA daily allowable ephedrine content was constant at 2.8 to 3.3%, and the weight ratio of ephedra powder, and the stable weight ratio of the side-effect-preventing powder agent for each constitution with respect to the ephedra powder, was different. According to the analysis report of patients who visited the applicant's clinic in 2017, although the amount of the ephedra powder varied depending on the time and location of the ephedra, when the ephedrine content is constant at 3.0-4.0%, about 360 g was in Taeeumin, about 297 g was in Soeumin, and about 360 g was in Soyangin; and when the weight ratio of the constitutional stable side-effect-preventing powder agent with respect to the ephedra powder was 1:8-10 in Taeeumin, 1:9-11 in Soeumin, and 1:8-10 in Soyangin, and when the reduction ratio and side effects were analyzed for 278 patients who visited the applicant's clinic again after taking the composition for each constitution for 3 months, as shown in Table 3 and Table 4, it was determined that the ephedrine content was 3.0-4.0%, indicating a weight effect within the effective range for each constitution.

(27) Table 3 shows the results of experiments of the appropriate weight of ephedra powder by Sasang medical constitution.

(28) TABLE-US-00003 TABLE 3 Ephedra powder Weight (g) 400 380 360 340 320 300 280 Taeeumin Appeal for Appeal for Appeal for Insufficient Insufficient Insufficient Insufficient weight loss weight loss weight loss weight loss weight loss weight loss weight loss side effect side effect side effect within within within within within within within effective effective effective effective effective effective effective range range range range range range range Soeumin Appeal for Appeal for Appeal for Appeal for Appeal for Appeal for Insufficient weight loss weight loss weight loss weight loss weight loss weight loss weight loss side effect side effect side effect side effect side effect side effect within within within within within within within effective effective effective effective effective effective effective range range range range range range range Soyangin Appeal for Appeal for Weight loss Insufficient Insufficient Insufficient Insufficient weight loss weight loss within weight loss weight loss weight loss weight loss side effect side effect effective within within within within within within range effective effective effective effective effective effective range range range range range range

(29) According to the results of Table 3, the weight of the ephedra powder, which showed the weight loss effect within the effective range for each constitution, was determined when the ephedrine content is constant at 3.0 to 4.0%; and for the weight of the ephedra powder, which showed weight loss within the effective range, it was determined whether side effects did not appear, while showing weight loss within the effective range when the weight of the side-effect-preventing powder agent for each constitution for constitutional stability varied. Here, even a case in which one of the patients who visited the clinic complained of side effects was indicated as the side effect appearance, and the weight loss within the effective range was the case of weight loss less than 5% when measured after 3 months.

(30) Table 4 shows the weight of the side-effect-preventing powder agent by constitution, whether or not weight loss by constitution, and whether or not side effects occurred.

(31) TABLE-US-00004 TABLE 4 Constitutional side-effect-preventing powder agent/weight 20 g 30 g 40 g 50 g 60 g 70 g 80 g Taeeumin/(Ephedra Complaint of Complaint of Weight loss Insufficient Complaint of Insufficient Complaint of powder 360 g) weight loss weight loss within weight loss insufficient weight loss insufficient side effect side effect effective within weight loss within weight loss within within range effective side effect effective side effect effective effective range within effective range within effective range range range range Soeumin/(Ephedra Complaint of Weight loss Complaint of Complaint of Complaint of Complaint of Complaint of powder 300 g) weight loss within weight loss insufficient insufficient weight loss insufficient side effect effective side effect weight loss weight loss side effect weight loss within range within side effect side effect within side effect effective effective within within effective within range range effective effective range effective range range range Soyangin/(Ephedra Complaint of Complaint of Weight loss Insufficient Complaint of Insufficient Complaint of powder 360 g) weight loss weight loss within weight loss insufficient weight loss insufficient side effect side effect effective within weight loss within weight loss within within range effective side effect effective side effect effective effective Weight loss range within effective range within range range within Insufficient range Insufficient effective Complaint of Complaint of effective weight loss Insufficient weight loss range weight loss weight loss range within weight loss within Insufficient side effect side effect effective within effective effective weight loss within within range range range within effective effective effective range range range

(32) That is, in the case of Taeeumin, the weight loss within the effective range was shown for 360 g of ephedra powder, but it was found that when the ratio of the ephedra power and the side-effect-preventing powder agent for each constitution was larger than 8-10:1, there were cases in which weight loss was not achieved within the effective range, and people complaining of side effects appeared.

(33) In addition, in the case of Soeumin, the weight loss within the effective range was shown for 300 g of ephedra powder, but it was found that when the ratio of the ephedra power and the side-effect-preventing powder agent for each constitution was larger than 9-11:1, there were cases in which weight loss was not achieved within the effective range, and people complaining of side effects appeared.

(34) In addition, in the case of Soeumin, the weight loss within the effective range was shown for 300 g of ephedra powder, but it was found that when the ratio of the ephedra power and the side-effect-preventing powder agent for each constitution was larger than 9-11:1, there were cases in which weight loss was not achieved within the effective range, and people complaining of side effects appeared.

(35) Meanwhile, the height, initial weight, body fat mass, and initial muscle mass of patients to which Experimental Example 2 was applied and who visited the Korean clinic of the applicant in 2017 showing the results of Table 3 and Table 4, are as follows.

(36) Table 5 is a table summarizing information about the height, initial weight, initial body fat mass, and initial muscle mass of patients who visited the applicant's clinic in 2017.

(37) TABLE-US-00005 TABLE 5 Standard Item Average Deviation Minimum Maximum Height (cm) 161.37 6.49 142.00 186.80 Initial weight (kg) 72.23 15.16 50.08 161.64 Initial body fat mass (kg) 28.12 8.82 12.60 67.86 Initial muscle mass (kg) 24.01 4.75 17.10 54.7

(38) Therefore, according to the result of analyzing the weight loss ratio of 278 people after taking the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine prescribed by considering the weight ratio of the side effects preventing powder agent for each constitution with respect to the ephedra powder agent as in the result of Experimental Example 2 considering each constitution, for 3 months (strictly 10 to 12 weeks), as shown in FIG. 2, the average weight loss was 6.88 kg, and the difference was statistically significant (p-value=0.000).

(39) Success in losing weight in obesity treatment is defined as losing 5 to 10% of weight, and the weight loss ratio of the present composition was 9.37% on average, indicating that it was close to successful weight loss in both medical and clinical aspects.

(40) In addition, as shown in Table 6, 243 patients (87.4%) of the 278 patients lost 5% or more of their body weight, and 115 patients of 278 patients (41.4%) lost 10% or more of their body weight. Therefore, it can be seen that 87.4% (87 out of 100) of the patients who visited Nubebe Korean medicine clinic may lose 5% or more of their weight.

(41) Table 6 is a table showing the percentage distribution of weight loss among patients who visited the applicant's clinic.

(42) TABLE-US-00006 TABLE 6 Classification Number of patients Percent Weight loss of 5% or more 243 people 87.4% Weight loss of 10% or more 115 people 41.4%

(43) As shown in FIG. 3, as a result of comparing the changes in the initial body fat mass and the body fat mass after 3 months of taking the mediation, an average of 5.77 kg was lost and the difference was statistically significant (p-value=0.000). In the muscle mass, there was an average decrease of 0.56 kg, and there was also a statistically significant difference (p-value=0.000). However, the p-value is a probability value that is affected by a sample size, and tends to approach 0 as the sample size increases. That is, since data with sufficient or large sample sizes may show significant results even for very small differences, it is necessary for an analyst to check the statistical significance and to determine whether there is the substantial significance in the difference in results. In the muscle mass, a change of about 0.56 kg was observed before and after the actual treatment, and clinically, the weight loss effect of the present application may be considered to mainly originate from the body fat loss effect. In addition, as shown in Table 7, patients with normal weight lost an average of 7.99% compared to the first treatment, and patients with high obesity lost an average of 9.89% compared to the first treatment. Although the present composition achieved an effective weight loss effect even at the normal weight, it showed a successful weight loss especially in obese patients (including obesity and high obesity).

(44) Table 7 summarizes the percentage of weight loss with respect to the obesity state of patients who visited the applicant's clinic.

(45) TABLE-US-00007 TABLE 7 Classification Percentage of weight loss Normal Average weight loss of 7.99% Overweight Average weight loss of 8.02% Obesity Average weight loss of 9.36% Extreme obesity Average weight loss of 9.89%

(46) In addition, as shown in Table 8, regardless of the degree of obesity, in the analysis by weight band, among the 278 patients, the number of patients in the 50 kg band was 39, the number of patients in the 60 kg band was 117, the number of patients in the 70 kg band was 66, and the number of patients in the 80 kg band was 26, and the number of patients in the 90 kg band and the 100 kg or more band respectively was 15, respectively. Table 8 is a table showing weight loss by weight regardless of obesity.

(47) TABLE-US-00008 TABLE 8 Standard Average Standard Average deviation weight deviation of weight of weight loss weight loss Weight loss loss ratio ratio 50 kg band 4.74 kg 1.94 kg 8.33% 3.35% 60 kg band 5.80 kg 2.28 kg 8.93% 3.46% 70 kg band 7.67 kg 2.79 kg 10.25% 3.55% 80 kg band 7.75 kg 4.05 kg 9.12% 4.77% 90 kg band 9.78 kg 5.26 kg 10.37% 5.52% 100 kg band  12.89 kg 4.84 kg 11.06% 3.88% Total 6.87 kg 3.51 kg 9.37% 3.81%

(48) As shown in Table 8, it can be seen that as the weight increased from 50 kg to 100 kg or more, the average weight loss also increased. However, in the average weight loss ratio, it can be seen that the average weight loss ratio of patients of the 70 kg band was 10.25%, which was higher than the weight loss ratio of patients of the 80 kg band. The minimum and maximum values of the weight loss ratio of the patients of the 70 kg band were 3.27% and 20.96%, respectively, and the minimum and maximum values of the weight loss ratio of the patients of the 80 kg band were −0.99% and 18.27%, respectively, wherein the weight loss ratio of some patients was 0.60%. The average weight loss ratio increased to 9.89%, excluding the patients who gained weight and whose weight loss ratio was 0%, among patients of the 80 kg band. Therefore, among the patients of the 80 kg band, there was a patient who gained weight, and it can be seen that this had an effect on the average weight loss ratio. Based on clinical data, the weight loss effect of the present composition was close to successful weight loss in a medical and clinical sense, and considering the time taken, rapid weight loss was achieved in a short period of 10 weeks compared to other medicines (western medicine and herbal medicine).

(49) It can be seen that even in the process of complex preparation, the ephedra was extracted alone; the stability of the medicine was maintained by quantifying the indicator component; the safety of treatment was maintained by adjusting the content of the indicator component in consideration of weight and obesity; and it maintained an excellent treatment rate and reduced the duration of the dose, consequently improving the treatment rate.

(50) On the other hand, among the compositions of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to the embodiment of the present invention, in general, in the case of Taeeumin, obesity became a sensitive problem, and thus, a lipase inhibitory efficacy test of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine for Taeeumin, was performed.

Experimental Example 4

(51) The measurement of lipase activity of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine for Taeeumin, was measured using 4-dinitrophenyl butyrate as a substrate.

(52) A porcine pancreatic lipase from Sigma company, USA (0.5 mg/mL), was purchased, and was dissolved in a 0.1 mol potassium phosphate buffer solution, and then, in order to measure the lipase inhibitory efficacy of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine for Taeeumin, experiments were performed at five concentrations of 0.04%, 0.08%, 0.12%, 0.16%, and 0.2%, and measured 10 times per concentration.

(53) 0.4 mL of 4-dinitrophenyl butyrate solution was added to a mixed solution of the prepared 0.1 mL pancreatic lipase solution and 0.1 mL Gambijeong M solution, and 0.1 mL of 1M Tris-HCL solution was added thereto, and then it was reacted for 5 minutes at 37° C. in an incubator.

(54) Then, the activity of the lipase was determined by measuring the absorbance of 4-dinitrophenol isolated by the lipase with a spectrophotometer at 360 nm.

(55) The experimental results were represented as relative values of the lipase to the control at 100%, and the experimental result was found to be significant when the P value was 0.05% or less through the statistical program SPSS, as shown in Table 9 and Table 10.

(56) Table 9 is raw data of the lipase activity.

(57) TABLE-US-00009 TABLE 9 1 2 3 4 5 6 7 8 9 10 CON 22.43334 22.18817 22.67852 22.92369 22.92369 22.8011 22.8011 22.67852 22.67852 22.67852 Pan 103.2179 101.1339 100.0306 99.41771 99.04995 99.90806 99.66289 99.5403 100.3984 99.66289 S_0.04 96.72081 101.1339 103.9534 104.5663 104.3212 102.3598 102.1146 102.7276 102.605 103.4631 S_0.08 82.25559 89.51079 93.04321 93.04321 90.46889 91.44959 93.53356 93.53356 91.93993 91.93993 S_0.12 83.60405 80.53936 85.68802 83.84922 82.25559 83.35887 85.32026 84.58474 84.9525 90.95924 S_0.16 88.50751 81.52007 80.04903 78.82317 82.13301 82.86853 81.88783 82.37818 83.72663 82.50077 S_0.20 85.07508 77.47472 79.31352 77.47472 76.61661 78.08765 79.19093 81.64266 85.32026 84.58474

(58) Table 10 is a table showing the lipase activity with respect to “Gambijeong” for Taeeumin.

(59) TABLE-US-00010 TABLE 10 Density Lipase activity 0.00% 100.20 ± 1.14  0.04% 102.50 ± 2.17  0.08% 91.05 ± 3.19 0.12% 84.51 ± 2.73 0.16% 82.44 ± 2.55 0.20% 80.48 ± 3.41

(60) As shown in Table 10 and FIG. 4, the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine for Taeeumin showed significant lipase inhibitory ability from a 0.08% concentration, and it was also found that inhibiting lipase efficacy in the body could be utilized to lower the body's utilization of fat when taken with a high fat diet.

(61) On the other hand, from the experimental results for patients who visited the Korean clinic of the applicant, the patient's obesity (or BMI) and the usage of the composition based on the constitution could be standardized as shown in Table 11 by using the daily content of ephedrine.

(62) Table 11 shows the constitutional usage of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to the embodiment of the present invention, wherein Gambijeong 1 to Gambijeong 4 represent the division by the constitution of the herbal medicinal tablet formulation for treating obesity.

(63) TABLE-US-00011 TABLE 11 Ephedrine content Classification (1 day) Usage Gambijeong 1 60-90 mg Normal weight, overweight, initial obesity Gambijeong 2 80-120 mg Overweight, obesity Gambijeong 3 90-120 mg Moderate and severe obesity Gambijeong 4 130-140 mg Immunity, moderate, and high obesity

(64) A manufacturing method of an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine will now be described in detail with reference to FIG. 5 to FIG. 11. FIG. 5 illustrates a flowchart of a manufacturing method of an ephedra powder agent for an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to an embodiment of the present invention, and a side-effect-preventing powder agent by constitution, FIG. 6 illustrates a flowchart of a manufacturing method of an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to an embodiment of the present invention, FIG. 7 to FIG. 9 respectively illustrate a graph of measuring an ephedrine content every 2 hours for 10 lots in a decocting process for 4 different ephedra with different producing districts and collecting periods so as to manufacture an ephedra powder agent for an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to an embodiment of the present invention, and FIG. 10 and FIG. 11 respectively illustrate graphs for explaining a pattern relationship between a Brix content and an ephedrine content in manufacturing an ephedra powder agent for an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to an embodiment of the present invention, by using the results shown in FIG. 7 to FIG. 9.

(65) In FIG. 7 to FIG. 9, line 1 is pseudoephedrine content %, and line 2 is ephedrine content %.

(66) Generally, the herbal medicines are provided in various ways, such as decoctions, pills, powders, granule preparations, concentrated liquid preparations, and distillation agents, however, they are not suitable as a treatment for obesity, such as by having a peculiar smell, bitter taste, stickiness, or feeling of satiety due to excessive amounts, which are peculiar to herbal medicine preparations, and therefore, the manufacturing method of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to the embodiment of the present invention provides a tablet formulation for treating obesity that may be prescribed according to Sasang constitutional medicine so as to solve the above problems and achieve the obesity treatment effect without side effects according to the prescription for each constitution based on Sasang constitutional medicine.

(67) As shown in FIG. 7 and Table 12, first, the ephedrine content of ephedra was 0.185 for spring collection in China and 0.360 for collection in Pakistan, depending on the producing district and collecting period, wherein a difference between their content % was almost doubled by 0.09% and 0.18%, and thus, it can be seen that they did not reach 2.8 to 3.3% that were an amount of being able to treat obesity within 3 months.

(68) Table 12 show data for four ephedra of different producing districts and collecting periods.

(69) TABLE-US-00012 TABLE 12 Weight of extraction liquid Extraction Extraction Experimental Place of Raw Total liquid Extraction Brix time material origin Vessel material weight weight rate Average Measure 6 hr S1-1 Chinese 174.73 30.00 313.02 108.29 36.1% 136.40 6.4% spring S1-2 176.00 30.00 324.15 118.15 39.4% 6.1% S1-3 181.65 30.00 343.16 131.51 43.8% 5.3% S1-4 189.65 30.00 354.27 134.62 44.9% 5.2% S1-5 172.79 30.00 346.64 143.85 48.0% 4.8% S1-6 146.20 30.00 265.85 89.65 29.9% 8.3% S1-7 174.74 30.00 369.29 164.55 54.9% 4.4% S1-8 176.02 30.00 333.31 127.29 42.4% 5.6% S1-9 181.65 30.00 376.73 165.08 55.0% 4.6% S1-10 189.65 30.00 400.67 181.02 60.3% 4.0% S2-1 Chinese 172.80 30.00 378.30 175.50 58.5% 164.77 3.8% autumn S2-2 146.19 30.00 336.60 160.41 53.5% 4.1% S2-3 174.74 30.00 355.28 150.54 50.2% 4.5% S2-4 176.01 30.00 397.11 191.10 63.7% 3.5% S2-5 181.67 30.00 388.45 176.78 58.9% 3.8% S2-6 189.66 30.00 373.35 153.69 51.2% 4.3% S2-7 172.87 30.00 415.24 212.37 70.8% 3.2% S2-8 146.18 30.00 317.20 141.02 47.0% 4.6% S2-9 174.74 30.00 372.42 167.68 55.9% 3.9% S2-10 176.00 30.00 324.61 118.61 39.5% 5.2% S3-1 Pakistan 181.64 30.00 357.51 145.87 48.6% 160.64 6.0% S3-2 189.64 30.00 317.80 98.16 32.7% 8.1% S3-3 172.80 30.00 299.95 97.15 32.4% 8.2% S3-4 146.19 30.00 299.02 122.83 40.9% 7.0% S3-5 174.73 30.00 411.89 207.16 69.1% 4.3% S3-6 176.01 30.00 415.79 209.78 69.9% 4.2% S3-7 181.66 30.00 354.54 142.88 47.6% 6.1% S3-8 189.64 30.00 428.12 208.48 69.5% 4.4% S3-9 172.79 30.00 398.96 196.17 65.4% 4.5% S3-10 146.18 30.00 354.08 177.90 59.3% 5.0% S4-1 Kyrgyzstan 174.75 30.00 347.54 142.79 47.6% 123.90 6.2% S4-2 182.70 30.00 332.59 119.89 40.0% 7.2% S4-3 168.83 30.00 290.56 91.73 30.6% 9.2% S4-4 186.91 30.00 329.61 112.70 37.6% 7.7% S4-5 179.74 30.00 327.90 118.16 39.4% 7.2% S4-6 146.19 30.00 326.11 149.92 50.0% 5.8% S4-7 174.73 30.00 338.70 133.97 44.7% 6.3% S4-8 182.69 30.00 316.97 104.28 34.8% 7.5% S4-9 168.82 30.00 320.16 121.34 40.4% 7.0% S4-10 186.90 30.00 361.13 144.23 48.1% 6.1% Total alkaloid Extraction Extraction amount amount Total Extraction Pseudo Dose Total correction time Average Ephedrine Ephedrine Dose Average correction Average 6 hr 5.5% 0.04% 0.14% 0.18% 0.15% 0.28% 0.27% 0.03% 0.13% 0.16% 0.26% 0.03% 0.12% 0.15% 0.27% 0.03% 0.12% 0.15% 0.27% 0.03% 0.11% 0.14% 0.27% 0.04% 0.18% 0.22% 0.31% 0.03% 0.10% 0.13% 0.29% 0.03% 0.12% 0.15% 0.26% 0.02% 0.10% 0.12% 0.27% 0.02% 0.08% 0.10% 0.25% 4.1% 0.04% 0.07% 0.11% 0.12% 0.27% 0.26% 0.04% 0.08% 0.12% 0.26% 0.03% 0.07% 0.10% 0.20% 0.03% 0.07% 0.10% 0.28% 0.03% 0.07% 0.10% 0.24% 0.04% 0.09% 0.13% 0.27% 0.03% 0.07% 0.10% 0.34% 0.05% 0.09% 0.14% 0.26% 0.04% 0.08% 0.12% 0.27% 0.05% 0.10% 0.15% 0.25% 5.8% 0.04% 0.18% 0.22% 0.24% 0.43% 0.53% 0.05% 0.27% 0.32% 0.48% 0.05% 0.29% 0.34% 0.50% 0.06% 0.25% 0.31% 0.52% 0.03% 0.16% 0.19% 0.61% 0.03% 0.15% 0.18% 0.60% 0.04% 0.22% 0.26% 0.50% 0.04% 0.15% 0.19% 0.62% 0.03% 0.15% 0.18% 0.52% 0.03% 0.17% 0.20% 0.49% 7.0% 0.02% 0.19% 0.22% 0.24% 0.42% 0.41% 0.03% 0.22% 0.32% 0.53% 0.04% 0.26% 0.34% 0.49% 0.03% 0.23% 0.31% 0.50% 0.03% 0.22% 0.19% 0.31% 0.02% 0.17% 0.18% 0.36% 0.02% 0.20% 0.26% 0.47% 0.03% 0.23% 0.19% 0.29% 0.03% 0.21% 0.18% 0.30% 0.02% 0.19% 0.20% 0.39%

(70) Therefore, it is necessary to concentrate and quantify the active ingredient in order to extract ephedrine, which is an active ingredient of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to the embodiment of the present invention, only from the natural component ephedra.

(71) Here, the quantifying is for maintaining the ephedrine content of ephedra powder at a predetermined value, and a sugar measure, Brix, is used. Brix is precisely called Brix %, and this unit is an amount of solute dissolved in an aqueous solution as a unit of %, and it is a “soluble solid”, which means that a high Brix is high in a soluble solid, including salt, protein, acid, and the like as well as a sugar content, and it can be used as a measure of the ratio of ephedrine content by measuring very widely used Brix.

(72) To this end, the method for manufacturing the ephedra powder agent and side-effect-preventing powder agent for each constitution for the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to the embodiment of the present invention includes: small-dividing each of the ephedra for ephedra powder and the herbal ingredients prescribed for the side-effect-preventing powder agent for each constitution shown in Table 2, based on the weight per pack (S10); and primarily concentrating and quantifying ephedrine, which is an active ingredient, through the Brix measurement while undergoing a hydraulic decocting process (S20).

(73) The hydraulic decocting process, which is a process of facilitating the decocting by applying hydraulic pressure, generally includes: after washing with water, immersing in water at a temperature of 10 to 20° C., about 10 times for each weight, for 15 to 20 hours, to increase extraction of the active ingredient (S21); and then boiling each material at a temperature of 95 to 100° C. for 4 to 5 hours to extract an extract liquid having a high yield (S21); measuring Brix every heating time (S23); checking whether the extract liquid has 7 Brix or more (S24); when the Brix of the extract liquid is not more than 7 Brix, the heating time is increased, while when the Brix of the extract liquid is more than 7 Brix, filtering foreign materials using a nanofilter of 100 mesh (S25); and maintaining cooling at 40 to 50° C. to prevent microorganisms and storing it while stirring it to prevent precipitation of solids (S26).

(74) In the method for manufacturing the ephedra powder agent and side-effect-preventing powder agent for each constitution for the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to the embodiment of the present invention, the reason for primarily quantifying the ephedrine to 7 Brix or more using the hydraulic decocting process was that the Brix substantially increased with the heating time of the hydraulic decocting process as shown in FIGS. 10 and 11, but the ephedrine content of ephedra remained constant at approximately 7 Brix even if the producing districts and collecting periods of the ephedra were different, or it had a pattern of decreasing by pressure or temperature, thus there was no need to use unnecessary energy in a situation in which the yield of the active ingredient was kept constant.

Experimental Example 5

(75) The Brix measurement in the hydraulic decocting process and the content measurement of ephedrine in each Brix value were performed as follows.

(76) For four ephedra (by country of origin-made in China, Pakistan, Kyrgyzstan/by collecting period-Chinese spring and autumn harvest), namely S1 (Chinese, spring), S2 (Chinese, autumn), S3 (Pakistan), and S4 (Kyrgyzstan), the same specimen was divided into 10 batches and tested; the extraction conditions were 10 times the weight of the test material, and after heating, the extract was made every 2 hours from the point of 100° C.; the weight of each extract was calculated by weight (extract weight=total weight-container weight-raw material weight); the Brix value for each lot was measured using a Brix densitometer called a Refractometer, ATAGO PAL-1; and the total alkaloid and ephedrine contents were measured using HPLC and Shimadzu 20-A series.

(77) [Quantity Test]

(78) Measured as a total alkaloid [ephedrine (C.sub.10H.sub.15NO: 165.23 g/mol) and pseudoephedrine (C.sub.10H.sub.15NO: 165.23 g/mol)], standard solution: ephedrine hydrochloride (dried at 105° C. for 3 hours in advance), approximately 50 mg of the standard product is precisely weighed, and diluted methanol (1.fwdarw.2) is added thereto to make exactly 20 mL. 2 mL of this solution is accurately taken, and diluted methanol (1.fwdarw.2) is added thereto to make exactly 100 mL.

(79) Test solution: About 5 mL of the extract is precisely weighed, put it in a stoppered centrifuge tube, and 20 mL of diluted methanol (1.fwdarw.2) is added thereto and shaken for 30 minutes, and then is centrifuged to take the supernatant.

(80) Next, in order to maintain each material at a predetermined concentration, it is boiled at a temperature of 95 to 100° C. and extracted until the concentration reached 7 to 10 Brix for secondary quantification. 20 mL of methanol (1.fwdarw.2) diluted in the residue is again used, and the above operation is repeated twice. All the extracts are combined, and the diluted methanol (1.fwdarw.2) is added thereto to make exactly 100 mL.

(81) Detector: UV absorbing photometer (measurement wavelength 210 nm)

(82) Column: a stainless steel pipe having an inner diameter of 4-6 mm and a length of 15-20 cm is filled with 5-10 μm octadecylsilyl silica gel for liquid chromatography.

(83) Constant temperature around 45° C.

(84) Mobile phase: sodium lauryl sulfate solution (1.fwdarw.128)*acetonitrile*phosphate mixture (640:360:1)

(85) The results are shown in Table 13 and Table 14.

(86) TABLE-US-00013 TABLE 13 Brix (% Brix) 2 h 4 h 6 h China (spring) 3.30 4.30 5.50 China (autumn) 3.00 3.80 4.10 Pakistan 4.10 5.10 5.80 Kyrgyzstan 3.60 5.30 7.00

(87) TABLE-US-00014 TABLE 14 Total alkaloid (%) 2 h 4 h 6 h China (spring) 0.28 0.26 0.27 China (autumn) 0.32 0.26 0.26 Pakistan 0.55 0.67 0.53 Kyrgyzstan 0.44 0.46 0.41

(88) As can be seen from Table 13 and Table 14, according to the hydraulic decocting process, it is about 0.41% on average at 7 Brix, and the content of ephedrine is insufficient to make 3 to 4% of the ephedrine powder agent, and in the case of continuous heating, destruction of active ingredients such as ephedrine occurs, and thus, secondary ephedrine concentration extraction and quantification is performed using a vacuum low-temperature concentration process (S30).

(89) In order to again concentrate the extract extracted in the hydraulic decocting process at a high concentration while lowering the heating temperature and increasing the concentration rate under reduced pressure and in a vacuum, under reduced pressure conditions, the extract is vacuum-reduced and concentrated for 5 to 6 hours under the reduced pressure condition of 08 to 09 bar and the concentration temperature of 50° C. to 55° C.

(90) Meanwhile, even in this case, the concentration is also maintained constant using the Brix, and while confirming whether the concentration of each material becomes approximately 30 to 35 Brix, it is secondarily quantified to prepare a concentrate.

(91) Here, in order to increase and maintain the ephedrine content %, it is determined using a Brix densitometer whether the concentration of the ephedra concentrate is 30 to 35 Brix, and the reason is that, as shown in Table 15, the total alkaloid correction average content % also increases with an increase in the Brix according to a vacuum decompression container, but thereafter, in lyophilization, crystals are generated in the case of 10 to 20 Brix, or the ephedrine content is rather lowered under the influence of temperature and pressure in the case of 40 Brix or more.

(92) In addition, it was also possible to concentrate it up to 30 Brix through the hydraulic decocting process, but in this case, as described above, the content of ephedrine was reduced by heat, and the concentration time was increased by 2 to 3 times or more.

(93) Table 15 is a table summarizing problems that occur when the Brix increases through a hydraulic decocting process.

(94) TABLE-US-00015 TABLE 15 10 Brix 20 Brix 30 Brix 40 Brix 50 Brix Total alkaloid 1.1% 1.9% 2.8% 3.5% 5% correction average content % Problem Crystal Crystal Close to Ephedrine Ephedrine generation generation effective content content during during ephedrine reduction reduction lyophilization lyophilization content (temperature, (temperature, pressure pressure effect) effect)

(95) The ephedrine is secondarily concentrated and quantified by the vacuum low-temperature concentration process, and the averaged concentrate is lyophilized (freeze-dried) by mixing different concentrates for each lot and each batch (S40). The lyophilization is a drying method that removes moisture using the property of sublimating only the moisture in the sample when the sample is frozen and then reduced in pressure, and according to the lyophilization, compared to simple hot air drying, wind drying, or high temperature drying, the dried material contains a myriad of gaps, so it is easy to absorb moisture, so it is easy to rehydrate quickly and completely.

(96) Therefore, the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to the embodiment of the present invention has the effect of being disintegrated within 30 minutes when taken with water.

(97) Meanwhile, the ephedra concentrate concentrated at 30 to 35 Brix may also drop the ephedrine content %, which is the active ingredient of the ephedra concentrate, according to the freezing temperature and freezing time, and thus, after performing an experiment to find a suitable freezing temperature and time, the ephedrine content % was measured to confirm whether it was reduced.

(98) The concentrate of the secondary quantified concentrated at 2.8% ephedrine content was divided into 3000 ml trays of a lyophilizer, and the temperature and freezing time were varied to measure the ephedrine content % and shown in Table 16.

(99) Table 16 is a table showing a change in ephedrine content % according to a freezing temperature and a time.

(100) TABLE-US-00016 TABLE 16 Temperature (° C.) −0 to −10° C. −10 to −20° C. −20 to −30° C. −30 to −40° C. −40 to −50° C. −50 to −60° C. Time (h) 18 hours 14 hours 10 hours 8 hours 5 hours 3 hours Total alkaloid correction 2.8% 2.78% 2.77% 2.8% 2.5% 2.41% average content

(101) As a result of the test, it is determined that the freezing time at a temperature of −40 to −50° C. is suitable in terms of a time of 3 to 5 hours, but it is suitable to freeze it at −30 to −40° C. for 8 hours, which may be maintained within the error range even if it takes a long time to maintain the total alkaloid corrected average content %, that is, ephedrine content %.

(102) Subsequently, drying proceeds, and at this time, in order to preserve the ephedrine content % well, the experiment results are shown in Table 17 while varying the drying temperature, pressure, and time.

(103) Table 17 shows a change in ephedrine content % according to a drying condition.

(104) TABLE-US-00017 TABLE 17 Item 01 02 03 04 05 06 07 Temperature (° C.) −30 −20 −10 0 10 20 30 Pressure (mb) 50 50 50 5 5 0 0 Time (h) 12 hours 18 hours 24 hours 28 hours 32 hours 48 hours 60 hours Total alkaloid correction 2.31% 2.50% 2.52% 2.55% 2.56% 2.6% 2.81% average content

(105) As can be seen from Table 17, when the lyophilization was performed under the freezing condition at a temperature of −30 to −40° C. and a freezing time of 8 hours and the drying condition at a temperature of 30 to 40° C. and a freezing time of at least 60 hours, the active ingredient of the concentrated liquid was well preserved, and a high concentration and yield of the ephedra powder agent was obtained.

(106) The lyophilized phase dried in the lyophilization process (S40) was pulverized to make a powder of a 40 to 45 mesh size, and then screened with a sieve of 40 to 45 mesh to screen the pulverized powder medicine to a certain size (S50).

(107) The ephedrine content of the ephedra powder agent, which was a powder medicine of a predetermined size, prepared as described above, was measured (S60), and then predetermined amounts of the ephedra powder agent and the herbal medicine powder agent for each side-effect-preventing powder agent were hermetically packaged in bags (S70).

(108) A manufacturing method of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to the embodiment of the present invention will now be described in detail with reference to FIG. 6.

(109) In the manufacturing method of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine according to the embodiment of the present invention, the ephedra powder agent and the side-effect-preventing powder agent for each constitution are measured and mixed depending on the ephedrine content of the ephedra powder agent (S110).

(110) In this case, the prescription is checked by referring to a list of the patient's weight, obesity, constitution based on Sasang constitutional medicine, side effects, and the like (S120), and when it is necessary to correct the prescription, the amount of the side-effect-preventing powder agent for each constitution with respect to the amount of the ephedra powder agent or the weight of the ephedra powder agent is corrected within the range of 1:8-10 to 1:9-11 (S121).

(111) When the checking and correcting of the prescription are not required with reference to the list of the patient's weight, obesity, constitution based on Sasang constitutional medicine, side effects, and the like, in order to prepare tablet formulations such as croscarmellose sodium, microcrystalline cellulose, and magnesium stearate, which act as disintegrants or hardness agents, the subsidiary material is mixed and put into the tableting apparatus, and then as shown in FIG. 1, it is tableted to have a size having a thickness of 590±010 mm, a diameter of 176±020 mm, and a weight of 646 mg±50% (S130).

(112) After the tableting process (S130), in order to prevent the active ingredient from being destroyed when exposed to air, it is coated by installing the coating liquid in the fixed frame of the injector, opening the liquid adjustment nozzle of each injector, increasing the pressure of the liquid pump to 1 to 2 bar, letting the initial liquid flow for 3 minutes, and then adjusting the pressure and the amount of air in the liquid pump (S140).

(113) The coating condition is a 60-250 ml/min liquid volume at a speed of 2-7 rpm at a pressure of 5-6 kg/cm.sup.2 with a 12 Fmm nozzle size.

(114) It is coated with the coating solution and then cooled and dried at 25-30° C. for 20 minutes at a low speed; defective products are taken off, and the pills are packed in containers accommodating 90 tablets so as to be able to be taken three times a day for three months; and a label on which patient, constitution, ephedrine content %, and prescription information for each constitution is recorded is attached to the container.

Experimental Example 6

(115) To confirm that the herbal medicinal tablet formulation for treating obesity manufactured by the manufacturing method of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang Medicine according to an embodiment of the present invention was effective in reducing obesity, 93 subjects were dosed for 10 days or 5 days, respectively, and the appetite suppressing effect, convenience when taking it, absorption rate, and preference were checked.

(116) Although the content of the herbal medicine for each constitution was different, when confirming the results for the present invention, there was no variation for each constitution.

Experiment Method

(117) (1) After 3 months of taking it, 4 kinds of appetite suppression effects such as “none, normal, existence, and very good” were confirmed.

(118) (2) In order to check the convenience when taking it, the convenience degree as 4 kinds of “none, normal, existence, and very good” was confirmed from those who have taken the existing herbal decoction or capsule.

(119) (3) In order to check the absorption rate, the convenience degree as 4 kinds of “none, normal, existence, and very good” was confirmed from those who have taken the existing herbal decoction or capsule.

(120) (4) In order to check the overall preference, 4 preferences of “none, normal, existence, and very good” was confirmed from those who have taken the existing herbal decoction or capsule.

(121) Since the composition of the herbal medicinal tablet formulation (Gambijeong) for treating obesity which can be prescribed based on Sasang constitutional medicine according to the embodiment of the present invention mainly reduces body fat, it is first checked through experiments whether it has the clinical effectiveness of weight loss for Sasang constitution, whether the Gambitang composition as a decoction medicine is stable for Taeeumin, and whether there is a clinical effect of weight loss without side effects.

(122) Table 18 shows an experimental result of a clinical effect of Gambijeong on Taeeumin.

(123) TABLE-US-00018 TABLE 18 Appetite suppression Absorption effect Convenience rate Preference Very good 39 64 51 50 Existence 30 39 38 27 Normal 19 0 3 5 None 5 0 1 1 Total 93 93 93 93

(124) As can be seen in Table 18, the appetite suppression effect was found to be effective in 69 (74%) out of 93 patients; the convenience was found to be effective in 93 (100%) out of 93 patients; the absorption rate, which was improved compared to that of the existing decoction or capsule, was found to be effective in 89 (95%) out of 93 patients; and the overall preference was found to be effective in 77 (82%) out of 93 patients. It was confirmed that the herbal medicinal tablet formulation and manufacturing method for treating obesity which can be prescribed based on Sasang Medicine according to the embodiment of the present invention were more convenient, preferred, and improved in absorption rate compared to other methods of taking the traditional herbal medicine, and it was confirmed that the herbal medicine according to Example 6 had the appetite suppression effect.

INDUSTRIAL APPLICABILITY

(125) The herbal medicinal tablet formulation and manufacturing method for treating obesity which can be prescribed based on Sasang Medicine according to the embodiment of the present invention, since it is advantageous in that the herbal medicine varies in the content of the drug according to the constitution and the degree of the disease, even for the same disease, and thus the prescription varies, may provide the advantage of the herbal medicine, and may provide convenience and effective effects to a person taking it by increasing and quantifying the yield of the active ingredient.

(126) In addition, the herbal medicinal tablet formulation and manufacturing method for treating obesity which can be prescribed based on Sasang Medicine according to the embodiment of the present invention may provide an herbal medicine with low stability to be more convenient to take and to be quickly absorbed.

(127) While this invention has been described in connection with what is presently considered to be practical exemplary embodiments, it is to be understood that the invention is not limited to the disclosed embodiments.